Terms: = Prostate cancer AND TET2, Q6N021, MGC125715, KIAA1546, FLJ20032, ENSG00000168769, 54790
30 results:
1. Dysregulation of DNA epigenetic modulators during prostate carcinogenesis in an eastern Indian patient population: Prognostic implications.
Banerjee A; Bardhan A; Sarkar P; Datta C; Pal DK; Saha A; Ghosh A
Pathol Res Pract; 2024 Jan; 253():154970. PubMed ID: 38056136
[TBL] [Abstract] [Full Text] [Related]
2. tet2 guards against unchecked BATF3-induced CAR T cell expansion.
Jain N; Zhao Z; Feucht J; Koche R; Iyer A; Dobrin A; Mansilla-Soto J; Yang J; Zhan Y; Lopez M; Gunset G; Sadelain M
Nature; 2023 Mar; 615(7951):315-322. PubMed ID: 36755094
[TBL] [Abstract] [Full Text] [Related]
3. Glyphosate disturbs various epigenetic processes in vitro and in vivo - A mini review.
Bukowska B; Woźniak E; Sicińska P; Mokra K; Michałowicz J
Sci Total Environ; 2022 Dec; 851(Pt 2):158259. PubMed ID: 36030868
[TBL] [Abstract] [Full Text] [Related]
4. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract] [Full Text] [Related]
5. Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.
Reyes DK; Trock BJ; Tran PT; Pavlovich CP; Deville C; Allaf ME; Greco SC; Song DY; Bivalacqua TJ; Han M; Partin AW; Sartor AO; Rowe SP; Pienta KJ
Med Oncol; 2022 Apr; 39(5):63. PubMed ID: 35478055
[TBL] [Abstract] [Full Text] [Related]
6. Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations.
Nicolae A; Bouilly J; Lara D; Fataccioli V; Lemonnier F; Drieux F; Parrens M; Robe C; Poullot E; Bisig B; Bossard C; Letourneau A; Missiaglia E; Bonnet C; Szablewski V; Traverse-Glehen A; Delfau-Larue MH; de Leval L; Gaulard P
Mod Pathol; 2022 Aug; 35(8):1126-1136. PubMed ID: 35301414
[TBL] [Abstract] [Full Text] [Related]
7. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer.
He Y; Wei T; Ye Z; Orme JJ; Lin D; Sheng H; Fazli L; Jeffrey Karnes R; Jimenez R; Wang L; Wang L; Gleave ME; Wang Y; Shi L; Huang H
Nat Commun; 2021 Mar; 12(1):1521. PubMed ID: 33750801
[TBL] [Abstract] [Full Text] [Related]
8. TETology: Epigenetic Mastermind in Action.
Seethy A; Pethusamy K; Chattopadhyay I; Sah R; Chopra A; Dhar R; Karmakar S
Appl Biochem Biotechnol; 2021 Jun; 193(6):1701-1726. PubMed ID: 33694104
[TBL] [Abstract] [Full Text] [Related]
9. Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
Dono A; Takayasu T; Yan Y; Bundrant BE; Arevalo O; Lopez-Garcia CA; Esquenazi Y; Ballester LY
Neurosurgery; 2021 Feb; 88(3):592-602. PubMed ID: 33369669
[TBL] [Abstract] [Full Text] [Related]
10. A 38-gene model comprised of key tet2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence.
Kamdar S; Fleshner NE; Bapat B
BMC Cancer; 2020 Oct; 20(1):953. PubMed ID: 33008340
[TBL] [Abstract] [Full Text] [Related]
11. The DNA methylation landscape of advanced prostate cancer.
Zhao SG; Chen WS; Li H; Foye A; Zhang M; Sjöström M; Aggarwal R; Playdle D; Liao A; Alumkal JJ; Das R; Chou J; Hua JT; Barnard TJ; Bailey AM; Chow ED; Perry MD; Dang HX; Yang R; Moussavi-Baygi R; Zhang L; Alshalalfa M; Laura Chang S; Houlahan KE; Shiah YJ; Beer TM; Thomas G; Chi KN; Gleave M; Zoubeidi A; Reiter RE; Rettig MB; Witte O; Yvonne Kim M; Fong L; Spratt DE; Morgan TM; Bose R; Huang FW; Li H; Chesner L; Shenoy T; Goodarzi H; Asangani IA; Sandhu S; Lang JM; Mahajan NP; Lara PN; Evans CP; Febbo P; Batzoglou S; Knudsen KE; He HH; Huang J; Zwart W; Costello JF; Luo J; Tomlins SA; Wyatt AW; Dehm SM; Ashworth A; Gilbert LA; Boutros PC; Farh K; Chinnaiyan AM; Maher CA; Small EJ; Quigley DA; Feng FY
Nat Genet; 2020 Aug; 52(8):778-789. PubMed ID: 32661416
[TBL] [Abstract] [Full Text] [Related]
12. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with prostate cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract] [Full Text] [Related]
13. Exploring targets of tet2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
Kamdar S; Isserlin R; Van der Kwast T; Zlotta AR; Bader GD; Fleshner NE; Bapat B
Clin Epigenetics; 2019 Mar; 11(1):54. PubMed ID: 30917865
[TBL] [Abstract] [Full Text] [Related]
14. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG
Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073
[TBL] [Abstract] [Full Text] [Related]
15. Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
Pritchard AL; Johansson PA; Nathan V; Howlie M; Symmons J; Palmer JM; Hayward NK
PLoS One; 2018; 13(4):e0194098. PubMed ID: 29641532
[TBL] [Abstract] [Full Text] [Related]
16. Genetic factors influencing prostate cancer risk in Norwegian men.
Chen H; Ewing CM; Zheng S; Grindedaal EM; Cooney KA; Wiley K; Djurovic S; Andreassen OA; Axcrona K; Mills IG; Xu J; Maehle L; Fosså SD; Isaacs WB
Prostate; 2018 Feb; 78(3):186-192. PubMed ID: 29181843
[TBL] [Abstract] [Full Text] [Related]
17. Genetic Variants in Epigenetic Pathways and Risks of Multiple cancers in the GAME-ON Consortium.
Toth R; Scherer D; Kelemen LE; Risch A; Hazra A; Balavarca Y; Issa JJ; Moreno V; Eeles RA; Ogino S; Wu X; Ye Y; Hung RJ; Goode EL; Ulrich CM;
Cancer Epidemiol Biomarkers Prev; 2017 Jun; 26(6):816-825. PubMed ID: 28115406
[No Abstract] [Full Text] [Related]
18. tet2 binds the androgen receptor and loss is associated with prostate cancer.
Nickerson ML; Das S; Im KM; Turan S; Berndt SI; Li H; Lou H; Brodie SA; Billaud JN; Zhang T; Bouk AJ; Butcher D; Wang Z; Sun L; Misner K; Tan W; Esnakula A; Esposito D; Huang WY; Hoover RN; Tucker MA; Keller JR; Boland J; Brown K; Anderson SK; Moore LE; Isaacs WB; Chanock SJ; Yeager M; Dean M; Andresson T
Oncogene; 2017 Apr; 36(15):2172-2183. PubMed ID: 27819678
[TBL] [Abstract] [Full Text] [Related]
19. Rare Variation in tet2 Is Associated with Clinically Relevant prostate Carcinoma in African Americans.
Koboldt DC; Kanchi KL; Gui B; Larson DE; Fulton RS; Isaacs WB; Kraja A; Borecki IB; Jia L; Wilson RK; Mardis ER; Kibel AS
Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1456-1463. PubMed ID: 27486019
[TBL] [Abstract] [Full Text] [Related]
20. tet2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression.
Takayama K; Misawa A; Suzuki T; Takagi K; Hayashizaki Y; Fujimura T; Homma Y; Takahashi S; Urano T; Inoue S
Nat Commun; 2015 Sep; 6():8219. PubMed ID: 26404510
[TBL] [Abstract] [Full Text] [Related]
[Next]
